An Update in Management of Noncutaneous T-Cell Lymphomas.pdfVIP

Hindawi Publishing Corporation Advances in Hematology Volume 2010, Article ID 424786, 6 pages doi:10.1155/2010/424786 Review Article An Update in Management of Noncutaneous T-Cell Lymphomas Y. Y. Hwang and R. H. S. Liang Division of Haematology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong Correspondence should be addressed to R. H. S. Liang, rliang@hkucc.hku.hk Received 31 August 2010; Accepted 28 October 2010 Academic Editor: F. M. Foss Copyright © 2010 Y. Y. Hwang and R. H. S. Liang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. T-cell lymphoma is a heterogeneous group of diseases. Except for ALK positive anaplastic large cell lymphoma, T-cell lymphoma responds to conventional chemotherapy unfavourably, and most patients carry poor prognosis. In recent years, efforts have been made to improve the outcome of T-cell lymphoma patients. Novel agents, high-dose therapy, and allogeneic stem cell transplantation are studied, and various results are reported in literature. This paper looks into the prognostication and treatment approach of different entities of noncutaneous T-cell lymphoma and would focus on the latest updates in its management. 1. Introduction This paper looks into the various prognostic markers in T-cell lymphoma as well as the latest updates in its T-cell lymphoma accounts for 10 to 15 percent of all management. non-Hodgkin lymphomas worldwide.